Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing disease-modifying treatments for Alzheimer's disease (AD). Its lead candidate, sabirnetug (ACU193), is a humanized IgG2 monoclonal antibody selectively targeting soluble amyloid-beta oligomers (AOs). Sabirnetug is currently in the Phase 2 ALTITUDE-AD trial. The company also develops an Enhanced Brain Delivery (EBD) AO-targeted therapy and a subcutaneous sabirnetug formulation in collaboration with Halozyme.
expected 2026-11-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001628280-26-021413 | EDGAR | 84K words |
| 2025-03-27 | 2024-12-31 | 0001576885-25-000049 | EDGAR | 82K words |
| 2024-03-26 | 2023-12-31 | 0001576885-24-000047 | EDGAR | 81K words |
| 2023-03-27 | 2022-12-31 | 0001576885-23-000017 | EDGAR | 85K words |
| 2022-03-28 | 2021-12-31 | 0001193125-22-086775 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001628280-26-056199 | EDGAR | 21K words |
| 2025-11-12 | 2025-09-30 | 0001576885-25-000104 | EDGAR | 19K words |
| 2025-08-12 | 2025-06-30 | 0001576885-25-000093 | EDGAR | 19K words |
| 2025-05-13 | 2025-03-31 | 0001576885-25-000065 | EDGAR | 17K words |
| 2024-11-12 | 2024-09-30 | 0001576885-24-000098 | EDGAR | 18K words |
| 2024-08-13 | 2024-06-30 | 0001576885-24-000092 | EDGAR | 18K words |
| 2024-05-14 | 2024-03-31 | 0001576885-24-000064 | EDGAR | 17K words |
| 2023-11-13 | 2023-09-30 | 0001576885-23-000062 | EDGAR | 19K words |
| 2023-08-08 | 2023-06-30 | 0001576885-23-000050 | EDGAR | 18K words |
| 2023-05-09 | 2023-03-31 | 0001576885-23-000025 | EDGAR | 15K words |
| 2022-11-14 | 2022-09-30 | 0001193125-22-284583 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001193125-22-221297 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-16 | 0001628280-26-062137 | EDGAR | 6K words |
| 2026-08-12 | 0001628280-26-055940 | EDGAR | 3K words |
| 2026-03-26 | 0001628280-26-021189 | EDGAR | 3K words |
| 2026-03-16 | 0001628280-26-017885 | EDGAR | 2K words |
| 2026-01-12 | 0001628280-26-001774 | EDGAR | 6K words |
| 2025-11-12 | 0001576885-25-000102 | EDGAR | 3K words |
| 2025-11-10 | 0001628280-25-050800 | EDGAR | 1K words |
| 2025-08-12 | 0001576885-25-000091 | EDGAR | 3K words |
| 2025-07-15 | 0001576885-25-000087 | EDGAR | 5K words |
| 2025-06-05 | 0001576885-25-000072 | EDGAR | 1K words |
84 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001576885 |
| Ticker | ABOS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.acumenpharm.com |
| Listed | 2021-07-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ABOS (~200 tokens, structured JSON with cryptographic provenance)